IL1B and pulmonary fibrosis: In this study, the administration of hESC-MSC-IMRCs or hESC-MSC-IMRC-CM exhibited an ability to suppress TNF-α, IL-1β, and IL-6 release in lung tissues of BLM-challenged mice, suggesting that hESC-MSC-IMRCs or hESC-MSC-IMRC-CM could mitigate pulmonary fibrosis by relieving inflammatory responses.